Welcome to our dedicated page for Opko Health SEC filings (Ticker: OPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company. These documents include current reports on Form 8-K and other periodic reports in which OPKO discloses financial results, significant transactions and operational updates.
Form 8-K current reports capture material events such as the announcement of quarterly operating and financial highlights and the completion of notable transactions. For example, OPKO has filed an 8-K describing a press release with results of operations and financial condition for a quarter, and another 8-K detailing the completion of the sale of certain BioReference Health oncology and related clinical assets to Labcorp under an asset purchase agreement.
Through its SEC filings, OPKO outlines segment performance in its pharmaceutical and diagnostics activities, provides information on capital structure changes such as convertible note exchanges, and describes collaboration agreements and asset sales. Exhibits to these filings often include press releases that summarize business highlights and explain how to access related conference calls and webcasts.
On Stock Titan, OPKO’s SEC filings are updated as they become available from the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as quarterly results, transaction terms, and other events described in Forms 8-K and other filings. Users can quickly identify filings that discuss diagnostics operations at BioReference, collaborations involving ModeX Therapeutics, and other developments that OPKO reports to regulators and investors.